Farreny A, Aguado J, Ochoa S, Haro JM, Usall J. The role of negative symptoms in the context of cognitive remediation for schizophrenia. Schizophr Res. 2013 Oct;150(1):58-63.
Farreny A, Aguado J, Ochoa S, Huerta-Ramos E, Marsà F, López-Carrilero R, Carral V, Haro JM, Usall J. REPYFLEC cognitive remediation group training in schizophrenia: looking for an integrative approach. Schizophr Res. 2012 Dec;142(1-3):137-44. doi: 10.1016/j.schres.2012.08.035.
Akashi-Ronquest N, Carrillo P, Dembling B, Stern S. Measuring the biases in self-reported disability status: evidence from aggregate data. Appl Econ Lett. 2011 Feb 23;18(11):1053-60. doi: 10.1080/13504851.2010.524603
Graham CN, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating an industry-sponsored model comparing the cost-effectiveness of atypical antipsychotics in the treatment of schizophrenia. Schizophr Res. 2010 Apr 1;117(2-3):398-9.
Rousu M, Kosa K. Allowing options in experimental auctions. Appl Econ Lett. 2005;12(13):817-21. doi: 10.1080/13504850500193059